Ecuador vs Malaysia: HIV/AIDS deaths averted by antiretroviral therapy
Ecuador
3,034 deaths
in 2024
Malaysia
2,430 deaths
in 2024
Ecuador rank
49th
Malaysia rank
52nd
HIV/AIDS deaths averted by antiretroviral therapy over time
- Ecuador
- Malaysia
How they compare
Ecuador currently reports 3,034 deaths against 2,430 deaths in Malaysia, a difference of 604 deaths.
That makes Ecuador's figure about 1.2 times Malaysia's.
The two have swapped places 5 times across 35 shared years of data; in 1990 it was Malaysia ahead.
Ecuador ranks 49th and Malaysia ranks 52nd of 157 countries.
Across the 4 decades both report, Ecuador averaged higher in 2 and Malaysia in 2.
Head to head by decade
| Decade | Ecuador | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 26.07 deaths | 2.35 deaths | 23.71 deaths | Ecuador |
| 2000s | 314.14 deaths | 917.24 deaths | 603.11 deaths | Malaysia |
| 2010s | 1,733 deaths | 1,987 deaths | 254.04 deaths | Malaysia |
| 2020s | 2,906 deaths | 2,627 deaths | 279.83 deaths | Ecuador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Ecuador or Malaysia?
- Ecuador, at 3,034 deaths against 2,430 deaths in Malaysia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Ecuador and Malaysia?
- 604 deaths, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and Malaysia?
- 35 years are reported by both, from 1990 to 2024.
- How do Ecuador and Malaysia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Ecuador ranks 49th and Malaysia ranks 52nd of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.